Brief: Bluebird Bio Announces First Outcomes-Based Agreement With Medicaid For Sickle Cell Disease Gene Therapy
11/03/2024 12:46
March 11 (Reuters) - bluebird bio Inc BLUE.O :
* BLUEBIRD BIO ANNOUNCES FIRST OUTCOMES-BASED AGREEMENT WITH
MEDICAID FOR SICKLE CELL DISEASE GENE THERAPY
* BLUEBIRD BIO INC: SIGNED ITS FIRST MEDICAID OUTCOMES-BASED
AGREEMENT FOR LYFGENIA WITH STATE OF MICHIGAN
Source text for Eikon: ID:nBwbbf4cqa
Further company coverage: BLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on bluebird bio
See all newsBrief: Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital
Brief: Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
Brief: Carlyle, SK Capital Partners And Bluebird Bio Provide Updated Tender Instructions
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Robinhood, Oklo, Chimera Investment